Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
???displayArticle.abstract??? ATP-binding cassette transporters protect cells via efflux of xenobiotics and endogenous byproducts of detoxification. While the cost of this ATP-dependent extrusion is known at the molecular level, i.e. the ATP used for each efflux event, the overall cost to a cell or organism of operating this defense is unclear, especially as the cost of efflux changes depending on environmental conditions. During prolonged exposure to xenobiotics, multidrug transporter activity could be costly and ineffective because effluxed substrate molecules are not modified in the process and could thus undergo repeated cycles of efflux and re-entry. Here we use embryos of the purple sea urchin, Strongylocentrotus purpuratus, as a model to determine transport costs and benefits under environmentally relevant xenobiotic concentrations. Strikingly, our results show that efflux transporter activity costs less than 0.2% of total ATP usage, as a proportion of oxygen consumption. The benefits of transport, defined as the reduction in substrate accumulation due to transporter activity, depended largely, but not entirely, on the rate of passive flux of each substrate across the plasma membrane. One of the substrates tested exhibited rapid membrane permeation coupled with high rates of efflux, thus inducing rapid and futile cycles of efflux followed by re-entry of the substrate. This combination significantly reduced transporter effectiveness as a defense and increased costs even at relatively low substrate concentrations. Despite these effects with certain substrates, our results show that efflux transporters are a remarkably effective and low-cost first line of defense against exposure to environmentally relevant concentrations of xenobiotics.
Aänismaa,
P-Glycoprotein kinetics measured in plasma membrane vesicles and living cells.
2007, Pubmed
Aänismaa,
P-Glycoprotein kinetics measured in plasma membrane vesicles and living cells.
2007,
Pubmed
Aller,
Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding.
2009,
Pubmed
Al-Shawi,
Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein.
2003,
Pubmed
Anderson,
Evaluation of methods to determine causes of sediment toxicity in San Diego Bay, California, USA.
2010,
Pubmed
Bains,
Alterations in respiration rate of isolated rainbow trout hepatocytes exposed to the P-glycoprotein substrate rhodamine 123.
2005,
Pubmed
Bard,
Assessing neuroprotective P-glycoprotein activity at the blood-brain barrier in killifish (Fundulus heteroclitus) using behavioural profiles.
2007,
Pubmed
Begley,
ABC transporters and the blood-brain barrier.
2004,
Pubmed
Behravan,
Drug transport across the placenta, role of the ABC drug efflux transporters.
2007,
Pubmed
Boesch,
In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
1991,
Pubmed
Bow,
Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes.
2008,
Pubmed
Broxterman,
Glycolysis in P-glycoprotein-overexpressing human tumor cell lines. Effects of resistance-modifying agents.
1989,
Pubmed
Broxterman,
Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells.
1988,
Pubmed
Choudhuri,
Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters.
2006,
Pubmed
Crowley,
Controlling the intracellular localization of fluorescent polyamide analogues in cultured cells.
2003,
Pubmed
Davidson,
Structure, function, and evolution of bacterial ATP-binding cassette systems.
2008,
Pubmed
Dawson,
Structure of a bacterial multidrug ABC transporter.
2006,
Pubmed
Döppenschmitt,
Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
1999,
Pubmed
Epel,
Efflux transporters: newly appreciated roles in protection against pollutants.
2008,
Pubmed
Essodaigui,
Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein.
1998,
Pubmed
Eytan,
The role of passive transbilayer drug movement in multidrug resistance and its modulation.
1996,
Pubmed
Eytan,
Mechanism of action of P-glycoprotein in relation to passive membrane permeation.
1999,
Pubmed
Eytan,
Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate.
1997,
Pubmed
Eytan,
Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis.
1996,
Pubmed
Gekeler,
The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance.
1995,
Pubmed
Gökirmak,
Localization and substrate selectivity of sea urchin multidrug (MDR) efflux transporters.
2012,
Pubmed
,
Echinobase
Greenberger,
Domain mapping of the photoaffinity drug-binding sites in P-glycoprotein encoded by mouse mdr1b.
1991,
Pubmed
Hall,
Is resistance useless? Multidrug resistance and collateral sensitivity.
2009,
Pubmed
Hamdoun,
Activation of multidrug efflux transporter activity at fertilization in sea urchin embryos (Strongylocentrotus purpuratus).
2004,
Pubmed
,
Echinobase
Hamdoun,
Embryo stability and vulnerability in an always changing world.
2007,
Pubmed
Higgins,
Multiple molecular mechanisms for multidrug resistance transporters.
2007,
Pubmed
Hildebrand,
Functional and energetic characterization of P-gp-mediated doxorubicin transport in rainbow trout (Oncorhynchus mykiss) hepatocytes.
2009,
Pubmed
Holland,
ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans.
1999,
Pubmed
Kabanov,
An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers.
2003,
Pubmed
Kalliokoski,
Impact of OATP transporters on pharmacokinetics.
2009,
Pubmed
Kolpin,
Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance.
2002,
Pubmed
Leong,
Na+/K+-ATPase activity during early development and growth of an Antarctic sea urchin.
1999,
Pubmed
,
Echinobase
Leong,
Metabolic importance of Na+/K+-ATPase activity during sea urchin development.
1997,
Pubmed
,
Echinobase
Mathews,
Giant pools of DNA precursors in sea urchin eggs.
1975,
Pubmed
,
Echinobase
Morris,
Interaction of forskolin with the P-glycoprotein multidrug transporter.
1991,
Pubmed
Niemi,
Role of OATP transporters in the disposition of drugs.
2007,
Pubmed
Pannevis,
The energetic cost of protein synthesis in isolated hepatocytes of rainbow trout (Oncorhynchus mykiss).
1992,
Pubmed
Patzlaff,
The ATP/substrate stoichiometry of the ATP-binding cassette (ABC) transporter OpuA.
2003,
Pubmed
Pawagi,
Transmembrane aromatic amino acid distribution in P-glycoprotein. A functional role in broad substrate specificity.
1994,
Pubmed
Pleban,
P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach.
2005,
Pubmed
Pluchino,
Collateral sensitivity as a strategy against cancer multidrug resistance.
2012,
Pubmed
Polli,
Rational use of in vitro P-glycoprotein assays in drug discovery.
2001,
Pubmed
Ramirez Llodra,
Fecundity and life-history strategies in marine invertebrates.
2002,
Pubmed
Raub,
P-glycoprotein recognition of substrates and circumvention through rational drug design.
2006,
Pubmed
Rees,
ABC transporters: the power to change.
2009,
Pubmed
Regev,
Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
2007,
Pubmed
Ricardo,
An ABC transporter controls export of a Drosophila germ cell attractant.
2009,
Pubmed
Rodríguez Robledo,
A study of the analytical behaviour of selected new molecular entities using electrospray ionisation ion trap mass spectrometry, liquid chromatography, gas chromatography and polarography and their determination in serum at therapeutic concentrations.
2008,
Pubmed
Rosenberg,
Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding.
2003,
Pubmed
Sauna,
Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein.
2000,
Pubmed
Schmell,
Phospholipid metabolism in the eggs and embryos of the sea urchin Arbacia punctulata.
1974,
Pubmed
,
Echinobase
Seeger,
Molecular basis of multidrug transport by ABC transporters.
2009,
Pubmed
Shapiro,
Reconstitution of drug transport by purified P-glycoprotein.
1995,
Pubmed
Smital,
Emerging contaminants--pesticides, PPCPs, microbial degradation products and natural substances as inhibitors of multixenobiotic defense in aquatic organisms.
2004,
Pubmed
,
Echinobase
Sodergren,
The genome of the sea urchin Strongylocentrotus purpuratus.
2006,
Pubmed
,
Echinobase
Szakács,
Targeting multidrug resistance in cancer.
2006,
Pubmed
Tran,
The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells.
2005,
Pubmed
von Richter,
A novel screening strategy to identify ABCB1 substrates and inhibitors.
2009,
Pubmed